6188-25-6

Basic information

• Product Name: 6-CHLOROIMIDAZO[1,2-A]PYRIDINE
• Synonyms: 6-CHLOROIMIDAZO[1,2-A]PYRIDINE
• CAS NO: 6188-25-6
• Molecular Formula: C₇H₅ClN₂
• Molecular Weight: 152.58
• EINECS: 1592732-453-0
• Mol File: 6188-25-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 85-87°C
• Boiling Point: 132°C/1.5mmHg(lit.)
• Appearance: /
• Density: 1.35 g/cm³
• Refractive Index: 1.653
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.18±0.50(Predicted)
• CAS DataBase Reference: 6-CHLOROIMIDAZO[1,2-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLOROIMIDAZO[1,2-A]PYRIDINE(6188-25-6)
• EPA Substance Registry System: 6-CHLOROIMIDAZO[1,2-A]PYRIDINE(6188-25-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 6188-25-6(Hazardous Substances Data)

Usage

Description

6-Chloroimidazo[1,2-a]pyridine is a pyridine derivative characterized by the presence of a chloro substituent at the 6th position and an imidazole ring fused to the pyridine nucleus. This chemical structure endows it with unique properties that make it a valuable compound in various applications, particularly in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
6-Chloroimidazo[1,2-a]pyridine is used as a pharmaceutical intermediate for the synthesis of various therapeutic agents. Its unique chemical structure allows it to serve as a building block in the development of new drugs with potential applications in treating a wide range of diseases and medical conditions.
As a pharmaceutical intermediate, 6-chloroimidazo[1,2-a]pyridine plays a crucial role in the synthesis of various active pharmaceutical ingredients (APIs). Its presence in the molecular structure of these APIs can contribute to their biological activity, selectivity, and pharmacokinetic properties, making it an essential component in the development of novel therapeutic agents.
Furthermore, 6-chloroimidazo[1,2-a]pyridine can be used in the design and synthesis of prodrugs, which are biologically inactive compounds that are converted into active drugs within the body. This approach can improve the solubility, stability, and bioavailability of the final drug product, enhancing its therapeutic efficacy and safety profile.
In addition to its role as a pharmaceutical intermediate, 6-chloroimidazo[1,2-a]pyridine may also find applications in other industries, such as agrochemicals, where it can be used as a precursor for the synthesis of various agrochemical products, including pesticides and herbicides.

InChI:InChI=1/C7H5ClN2/c8-6-1-2-7-9-3-4-10(7)5-6/h1-5H

Upstream product

• 107-20-0 2-chloroethanal 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 1072-98-6 5-chloro-2-pyridylamine 

Downstream Products

• 886371-28-4 3-bromo-6-chloroimidazo[1,2-a]pyridine 
• 885275-59-2 6-chloro-3-iodoimidazo[1,2-a]pyridine 
• 930113-27-2 8-chloro-3-phenylimidazo[1,2-α]pyridine 
• 900019-38-7 methyl 6-chloroimidazo[1,2-a]pyridine-3-carboxylate 
• 328062-45-9 6-phenylimidazo[1,2-a]pyridine 
• 1467063-99-5 6-chloro-3-(4-chlorophenyl)imidazo[1,2-a]pyridine 
• 1467064-02-3 6-chloro-3-(3-fluorophenyl)imidazo[1,2-a]pyridine 
• 1467064-01-2 6-chloro-3-(2-chlorophenyl)imidazo[1,2-a]pyridine 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

ORGANIC COMPOUNDS

Compounds of formula (I): in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treati ng diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical composit ions that contain the compounds and processes for preparing the compounds are also described.